The Clinical Need for Muscle MRI in ALS Biomarker Research

Amyotrophic lateral sclerosis presents significant diagnostic and monitoring challenges for neurologists worldwide. Clinicians often rely on functional rating scales and survival endpoints to assess clinical progression. However, these traditional measures carry subjective variability and require prolonged observation intervals. Consequently, investigators urgently need objective, non-invasive, and operator-independent biomarkers to accelerate therapeutic development. Emerging evidence highlights the diagnostic power of quantitative muscle MRI in ALS to track lower motor neuron degeneration. Denervation causes progressive skeletal muscle atrophy and structural degradation long before overt mobility loss occurs. While central nervous system imaging often yields variable results in motor neuron disease, peripheral skeletal muscle imaging directly visualizes downstream end-organ damage. Therefore, skeletal muscle neuroimaging bridges the gap between microscopic denervation and gross functional impairment. Furthermore, standardized quantitative MRI parameters offer reproducible outcome metrics that clinicians can reliably monitor across longitudinal evaluations. By detecting subclinical parenchymal remodeling, magnetic resonance imaging provides a granular view of therapeutic response. As novel neuroprotective agents enter clinical pipelines, objective imaging biomarkers will likely transform trial feasibility and patient care paradigms globally.

Study Design and Advanced Neuroimaging Protocol

A prospective longitudinal cohort study led by Dr. Uros Klickovic and colleagues evaluated muscle imaging over a one-year timeframe. Specifically, the researchers recruited twenty patients diagnosed with amyotrophic lateral sclerosis alongside sixteen healthy matched controls. Investigators acquired comprehensive multi-region scans at three distinct time points across the individual maximum observation period. The comprehensive scanning protocol encompassed the head-neck musculature, upper limb regions, and lower limb segments. Additionally, the team gathered detailed functional assessments and standardized myometry data during each clinical evaluation. The neuroimaging framework evaluated multiple objective parameters to capture disease activity. These quantitative measures included cross-sectional area, total muscle volume, intramuscular fat fraction, functional rest muscle area, and water T2 relaxation times. Moreover, the longitudinal protocol minimized inter-observer variability through automated and rigorous semi-automated segmentation methods. Seventeen patients completed the full multi-timepoint follow-up protocol during the study period. Ultimately, this robust longitudinal methodology enabled precise tracking of structural alterations against established functional benchmarks over twelve months.

Key Quantitative Findings Across Anatomical Regions

The research demonstrated profound, progressive muscle wasting across multiple anatomical regions over the individual maximum observation period. In particular, the intrinsic hand muscles exhibited substantial cross-sectional area reduction and volume loss. Statistical analysis revealed significant longitudinal atrophy in hand muscles among affected individuals. Furthermore, axial head-neck musculature displayed noticeable denervation-induced wasting over time, showing a partial eta-squared of 0.47. In the lower extremities, progressive volume loss proved exceptionally pronounced. Specifically, quantitative measurements documented prominent atrophy in both thigh musculature and calf muscle compartments. Thigh muscle metrics demonstrated robust disease progression, while calf compartments showed comparable degradation trajectories. In contrast, healthy control participants maintained stable muscle cross-sectional area and volume across all observation intervals. Besides volume reduction, changes in functional rest muscle area accurately captured the active contraction of viable contractile tissue. Therefore, multi-segmental magnetic resonance evaluation reliably separates pathological tissue degeneration from normal age-related changes across diverse muscle groups.

Correlation with Motor Strength and Functional Outcomes

Importantly, the observed structural alterations correlated directly with validated clinical and physical strength measures. Investigators discovered strong linear associations between quantitative lower-limb muscle metrics and voluntary motor strength. For instance, progressive changes in thigh and calf muscle parameters aligned closely with knee extension force. Similarly, MRI degradation patterns exhibited a strong correlation with ankle plantar flexion strength. In the upper extremity, hand muscle volume decline directly paralleled reductions in grip strength over time. Beyond isolated dynamometry, neuroimaging changes tracked disease progression across validated functional rating scales. In fact, relative reductions in calf functional rest muscle area significantly correlated with total functional decline. Consequently, these radiological parameters mirror clinical deterioration that directly impacts everyday motor performance. Clinicians often find conventional clinical exams vulnerable to patient effort or fatigue fluctuations. In contrast, magnetic resonance measurements capture true parenchymal deterioration independently of day-to-day physical variability. Thus, the neuroimaging data provide biologically meaningful reflections of actual functional decline.

Implications for Future Clinical Trials and Clinical Practice

These findings carry significant implications for modern drug development and interventional trials in motor neuron diseases. Currently, trial designs depend heavily on survival metrics or subjective patient questionnaires. However, survival endpoints require large participant cohorts and prolonged observation windows to detect therapeutic efficacy. Because quantitative imaging reliably detects subclinical muscle loss, researchers can substantially optimize trial efficiency. Specifically, sensitive radiological biomarkers allow clinical investigators to decrease required sample sizes while preserving statistical power. Furthermore, shorter trial durations reduce participant burden and trial attrition rates significantly. In routine clinical practice, non-invasive imaging offers valuable objective data to supplement bedside neurological examinations. Neurologists can utilize longitudinal volumetric assessments to monitor atypical disease trajectories or assess treatment stabilization. Moreover, combining muscle neuroimaging with molecular biofluid markers may provide a multidimensional view of disease kinetics. Ultimately, adopting standardized quantitative imaging protocols will accelerate therapeutic validation and improve multidisciplinary motor neuron disease management.

Technical Considerations and Implementation in Clinical Workflows

Implementing quantitative imaging into neurodegenerative care pathways requires thoughtful consideration of technical parameters and scanner accessibility. Radiology departments can successfully integrate standard multi-slice Dixon sequences and T2 mapping without adding excessive scanner duration. In addition, standard 1.5 Tesla and 3.0 Tesla clinical MRI scanners easily support these standardized acquisition protocols. Medical centers must nevertheless ensure uniform coil positioning and anatomical land-marking to maintain longitudinal reproducibility. Moreover, advancements in artificial intelligence and deep-learning segmentation algorithms promise to automate volumetric workflows. Automated muscle segmentation dramatically reduces post-processing labor while eliminating inter-rater subjective discrepancies. Consequently, busy diagnostic imaging facilities can generate automated structural reports rapidly for treating neurologists. While initial deployment requires staff training, the resulting diagnostic accuracy offers immense clinical value. Healthcare institutions can therefore leverage existing radiological infrastructure to support motor neuron disease registries and clinical investigations. As standardized protocols mature, quantitative muscle evaluation will become increasingly accessible for tertiary and academic neurology centers worldwide.

Frequently Asked Questions

How does muscle MRI in ALS differ from standard neurological assessment?

Muscle MRI in ALS provides operator-independent, quantitative evaluations of anatomical muscle tissue. Standard neurological assessments rely on clinical functional scales and dynamometry, which depend on patient effort, fatigue, and clinician scoring variability. In contrast, quantitative imaging precisely tracks cross-sectional area, volume reduction, and intramuscular fat accumulation without subjective bias.

Which muscle groups show the most significant progressive atrophy on MRI?

In clinical research, the intrinsic hand muscles, head-neck musculature, and lower-limb muscle groups demonstrate the most pronounced progressive atrophy. In particular, thigh and calf compartments show marked longitudinal reductions in muscle volume and functional rest muscle area, correlating tightly with declining voluntary motor strength and clinical functional scores.

Can quantitative muscle MRI reduce the sample size needed for clinical trials?

Yes, quantitative muscle MRI can reduce sample sizes by serving as a highly sensitive, objective outcome measure. Because MRI detects microscopic tissue changes and subclinical atrophy before overt functional decline appears, clinical trials require fewer participants and shorter follow-up intervals to demonstrate meaningful therapeutic efficacy or disease slowing.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their independent clinical judgment when managing individual patients. Refer to the latest local and national guidelines for clinical practice.

References

1. Klickovic U et al. Muscle MRI quantifies disease progression in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2025 Aug 14. doi: 10.1136/jnnp-2024-335571. PMID: 40132878.


2. Jenkins TM, Burness C, Connolly DJ, Rao DG, Hoggard N, Mawson S, et al. Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity. Neurology. 2019;93(9):e895-e907.


3. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8(1):94-109.